NASDAQ:YARW Yarrow Bioscience Q4 2025 Earnings Report $26.26 -0.75 (-2.78%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$26.87 +0.61 (+2.31%) As of 09/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Yarrow Bioscience EPS ResultsActual EPS-$7.45Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AYarrow Bioscience Revenue ResultsActual Revenue$0.13 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AYarrow Bioscience Announcement DetailsQuarterQ4 2025Date2/27/2026TimeN/AConference Call DateFriday, February 27, 2026Conference Call Time7:00AM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Yarrow Bioscience Earnings HeadlinesYarrow Bioscience Closes $172.5 Million Public OfferingSeptember 14 at 7:29 PM | finance.yahoo.comYarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesSeptember 14 at 7:29 PM | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Yarrow Bioscience Announces Underwritten Equity Offering AgreementSeptember 14 at 4:50 PM | tipranks.comYarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesSeptember 14 at 4:05 PM | businesswire.comYarrow Bioscience Stock Falls 7% On Pricing Of $150 Mln Public OfferingSeptember 13 at 6:50 PM | rttnews.comSee More Yarrow Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email. Email Address About Yarrow BioscienceVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.View Yarrow Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed EarningsMarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundThe End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
